EGFR and lung adenocarcinoma: This observation is consistent with a recent report of a BRAFV600E mutation in an erlotinib-resistant lung adenocarcinoma specimen22 and recent data indicating that EGFR-mutant lung adenocarcinoma cells can often develop EGFR TKI resistance through RAF-MEK-ERK pathway activation23.